Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894355 | 0.86 | ABCB1 (0.47) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL12894338 | 0.86 | L3MBTL1 (0.50) | L3MBTL1MAPTNPSR1RXRARXRB | |
| SCHEMBL12894353 | 0.83 | CDK4 (0.44) | L3MBTL1MAPTRXRARXRBRXRG | |
| SCHEMBL12920480 | 0.82 | RXRA (0.47) | MAPTRXRARXRBRXRGNISCH | |
| SCHEMBL12894337 | 0.81 | MCL1 (0.49) | L3MBTL1MAPTNPSR1RXRARXRB | |
| SCHEMBL6763906 | 0.81 | CYP1A2 (0.53) | L3MBTL1MAPTNPSR1RXRARXRB | |
| SCHEMBL18161386 | 0.79 | KDM4E (0.47) | ALDH1A1NISCHTDP1MEN1KMT2A | |
| SCHEMBL12894342 | 0.79 | MAPT (0.45) | L3MBTL1MAPTRXRARXRBRXRG | |
| SCHEMBL12894334 | 0.78 | IDO1 (0.40) | L3MBTL1MAPTNPSR1RXRARXRB | |
| SCHEMBL13794516 | 0.78 | L3MBTL1 (0.67) | L3MBTL1MAPTNPSR1ALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879889-B2 | administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-7879889-B2 | administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-7563903-B2 | Acylaminothiazole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | ACAT1, GLS2, GLS | L3MBTL1 1882/4885MAPT 1489/4885NPSR1 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.